Sector ratings Eli Lilly and Company

Equities

Real-time Estimate Cboe BZX Other stock markets 18:19:36 15/12/2025 GMT			5-day change	1st Jan Change
1,061.39 ^USD	+3.30%		+5.97%	+36.94%

04:36pm	Eli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says	MT
04:05pm	US FDA grants priority voucher to J&J's blood cancer treatment	RE

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
ELI LILLY AND COMPANY	920B		A
JOHNSON & JOHNSON	510B		BBB
ABBVIE INC.	395B		AA
ROCHE HOLDING AG	340B		AA
ASTRAZENECA PLC	278B		A
NOVARTIS AG	254B		AAA
MERCK & CO., INC.	249B		A
NOVO NORDISK A/S	224B		A
AMGEN INC.	171B		A
GILEAD SCIENCES, INC.	149B		AAA
PFIZER INC.	147B		BBB
SANOFI	119B		A
VERTEX PHARMACEUTICALS INCORPORATED	115B		AA
BRISTOL-MYERS SQUIBB COMPANY	107B		A
GSK PLC	97.84B		AA
CHUGAI PHARMACEUTICAL CO., LTD.	90.26B		AA
ALLERGAN PLC	63.66B	-	-	-	-	-	-	-
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	59.5B		AA
ALNYLAM PHARMACEUTICALS, INC.	52.52B		AA	-
TAKEDA PHARMACEUTICAL COMPANY LIMITED	45.11B		AA
Average	219.38B		AA
Weighted average by Cap.			AA